Payment overview · 2025
General Payments
$1,093.91
69 reported records · 16 companies
Healthcare provider profile · identity verified
Justin M Moore, MD
Allopathic & Osteopathic Physicians|Family Medicine · ANDERSON, SC · NPI 1013178110
Verified facts
What the public records show
CMS Open Payments records show Justin M Moore, MD received $1,093.91 in general payments during 2025 across 69 reported records.
ABBVIE INC. accounted for 21.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 29 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Linzess, Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 161 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $235.31 | 21.5% | 21 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $186.31 | 17.0% | 13 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $151.83 | 13.9% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $123.80 | 11.3% | 11 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $57.28 | 5.2% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $54.80 | 5.0% | 3 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $42.69 | 3.9% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $36.11 | 3.3% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $33.35 | 3.0% | 2 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $30.85 | 2.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $30.43 | 2.8% | 2 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $24.34 | 2.2% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $24.16 | 2.2% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $23.22 | 2.1% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $19.97 | 1.8% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $19.46 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,093.91 | 69 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $165.99 | 18 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $151.83 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $105.52 | 10 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $99.82 | 7 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $99.82 | 7 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $87.37 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $87.37 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $82.96 | 8 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $80.87 | 5 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $57.28 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $54.80 | 3 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $42.69 | 2 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $42.69 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $38.20 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $36.11 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $31.12 | 1 | 2025 |
Source payment records
|
|||||
| EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Normalized: edwards sapien 3 transcatheter heart valve thv |
Device | Edwards Lifesciences Corporation | $30.85 | 1 | 2025 |
Source payment records
|
|||||
| Fintepla Normalized: fintepla |
Drug | UCB, Inc. | $24.34 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $24.16 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $23.22 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $19.46 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $18.28 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $17.60 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.82 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $16.53 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $15.47 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.96 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $14.96 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $14.96 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 89 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 55 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 92 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 57 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 106 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 161 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 47 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
57 | 15 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
55 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
47 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
92 | 30 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
106 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
70 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
161 | 33 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
89 | 21 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
24 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 610 | 176 |
| Levothyroxine Sodium | Levothyroxine Sodium | 529 | 136 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 431 | 67 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 380 | 109 |
| Omeprazole | Omeprazole | 370 | 115 |
| Gabapentin | Gabapentin | 349 | 97 |
| Lisinopril | Lisinopril | 345 | 99 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 334 | 90 |
| Amlodipine Besylate | Amlodipine Besylate | 319 | 95 |
| Tramadol Hcl | Tramadol Hcl | 286 | 53 |
| Metformin Hcl | Metformin Hcl | 277 | 88 |
| Alprazolam | Alprazolam | 269 | 37 |
| Pantoprazole Sodium | Pantoprazole Sodium | 252 | 71 |
| Trazodone Hcl | Trazodone Hcl | 228 | 60 |
| Pravastatin Sodium | Pravastatin Sodium | 221 | 60 |
| Carvedilol | Carvedilol | 208 | 57 |
| Losartan Potassium | Losartan Potassium | 197 | 57 |
| Prednisone | Prednisone | 186 | 122 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 185 | 43 |
| Zolpidem Tartrate | Zolpidem Tartrate | 185 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 177 | 63 |
| Tizanidine Hcl | Tizanidine Hcl | 174 | 49 |
| Famotidine | Famotidine | 169 | 47 |
| Ozempic | Semaglutide | 161 | 33 |
| Escitalopram Oxalate | Escitalopram Oxalate | 159 | 43 |
| Montelukast Sodium | Montelukast Sodium | 154 | 37 |
| Hydrochlorothiazide | Hydrochlorothiazide | 153 | 50 |
| Simvastatin | Simvastatin | 151 | 41 |
| Ondansetron Odt | Ondansetron | 149 | 42 |
| Duloxetine Hcl | Duloxetine Hcl | 141 | 37 |
| Lorazepam | Lorazepam | 139 | 23 |
| Clonazepam | Clonazepam | 136 | 22 |
| Meloxicam | Meloxicam | 132 | 37 |
| Furosemide | Furosemide | 127 | 42 |
| Mirtazapine | Mirtazapine | 127 | 31 |
| Citalopram Hbr | Citalopram Hydrobromide | 115 | 27 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 114 | 34 |
| Glipizide Er | Glipizide | 113 | 37 |
| Irbesartan | Irbesartan | 112 | 31 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 109 | 28 |
| Pregabalin | Pregabalin | 108 | 19 |
| Mounjaro | Tirzepatide | 106 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 105 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 99 | 28 |
| Metoprolol Succinate | Metoprolol Succinate | 95 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 93 | 29 |
| Jardiance | Empagliflozin | 92 | 30 |
| Azithromycin | Azithromycin | 91 | 78 |
| Cephalexin | Cephalexin | 91 | 78 |
| Sertraline Hcl | Sertraline Hcl | 90 | 25 |
| Diclofenac Sodium | Diclofenac Sodium | 89 | 31 |
| Eliquis | Apixaban | 89 | 21 |
| Allopurinol | Allopurinol | 88 | 32 |
| Fluoxetine Hcl | Fluoxetine Hcl | 85 | 18 |
| Benazepril Hcl | Benazepril Hcl | 79 | 24 |
| Buspirone Hcl | Buspirone Hcl | 77 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 74 | 20 |
| Temazepam | Temazepam | 72 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 71 | 19 |
| Trulicity | Dulaglutide | 70 | 19 |
| Propranolol Hcl Er | Propranolol Hcl | 68 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 67 | 60 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 64 | 19 |
| Valsartan | Valsartan | 64 | 19 |
| Potassium Chloride | Potassium Chloride | 63 | 20 |
| Baclofen | Baclofen | 58 | 13 |
| Linzess | Linaclotide | 57 | 15 |
| Fluconazole | Fluconazole | 56 | 36 |
| Farxiga | Dapagliflozin Propanediol | 55 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 55 | 24 |
| Ropinirole Hcl | Ropinirole Hcl | 54 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 53 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 52 | 14 |
| Bupropion Xl | Bupropion Hcl | 51 | 16 |
| Nortriptyline Hcl | Nortriptyline Hcl | 51 | 14 |
| Spironolactone | Spironolactone | 51 | 14 |
| Trintellix | Vortioxetine Hydrobromide | 51 | suppressed |
| Celecoxib | Celecoxib | 49 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 47 | 16 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 45 | 12 |
| Ibuprofen | Ibuprofen | 43 | suppressed |
| Nitroglycerin | Nitroglycerin | 42 | 18 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 41 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 39 | 13 |
| Atenolol | Atenolol | 37 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 37 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 37 | suppressed |
| Chlorthalidone | Chlorthalidone | 36 | 12 |
| Ezetimibe | Ezetimibe | 36 | 15 |
| Januvia | Sitagliptin Phosphate | 36 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 35 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 35 | suppressed |
| Synthroid | Levothyroxine Sodium | 35 | suppressed |
| Nystatin | Nystatin | 34 | 15 |
| Ipratropium Bromide | Ipratropium Bromide | 33 | 12 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 32 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 32 | suppressed |
| Torsemide | Torsemide | 32 | 11 |
| Warfarin Sodium | Warfarin Sodium | 32 | suppressed |
| Lovastatin | Lovastatin | 31 | suppressed |
| Topiramate | Topiramate | 31 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 30 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 30 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 29 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 29 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 27 |
| Donepezil Hcl | Donepezil Hcl | 28 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 27 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 27 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 27 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 26 | suppressed |
| Diazepam | Diazepam | 26 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 25 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 25 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 25 | suppressed |
| Glipizide | Glipizide | 25 | suppressed |
| Dexamethasone | Dexamethasone | 24 | 23 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 24 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 24 | 23 |
| Promethazine Hcl | Promethazine Hcl | 24 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 23 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 23 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 22 | suppressed |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Belsomra | Suvorexant | 21 | suppressed |
| Indomethacin | Indomethacin | 21 | suppressed |
| Lidocaine | Lidocaine | 21 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Cefdinir | Cefdinir | 20 | 19 |
| Humalog Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 20 | suppressed |
| Mupirocin | Mupirocin | 20 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | 12 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 18 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Novolog | Insulin Aspart | 18 | suppressed |
| Amoxicillin | Amoxicillin | 17 | 14 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 17 | suppressed |
| Eszopiclone | Eszopiclone | 17 | suppressed |
| Ketoconazole | Ketoconazole | 17 | 13 |
| Novolog Flexpen | Insulin Aspart | 17 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Colchicine | Colchicine | 16 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 16 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 16 | suppressed |
| Premarin | Estrogens, Conjugated | 16 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Nabumetone | Nabumetone | 15 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Austedo | Deutetrabenazine | 14 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 11 |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Epinephrine | Epinephrine | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Famciclovir | Famciclovir | 11 | suppressed |
| Ibu | Ibuprofen | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Nucynta | Tapentadol Hcl | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,093.91 · 69 records | ABBVIE INC. | AIRSUPRA, AREXVY, BEXSERO, BREZTRI, CAPLYTA, CREON, Cologuard Collection Kit, Dexcom G6 Transmitter, EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV), ELIQUIS, FANAPT, FARXIGA, Fintepla, GVOKE HYPOPEN, HETLIOZ, JARDIANCE, LEQVIO, LINZESS, MOUNJARO, Ozempic, QULIPTA, REXULTI, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, VRAYLAR, Wegovy, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error